NCI Seeks Genomic, Proteomic Markers for Hematopoietic Malignancies | GenomeWeb

NEW YORK (GenomeWeb News) – The National Cancer Institute plans to fund researchers seeking to develop and validate biomarkers that can be used to detect and predict progression of hematopoietic malignancies, such as Hodgkin and non-Hodgkin lymphoma, leukemia, multiple myeloma, and others.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.